FTHFaeth TherapeuticsSigning up patients
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
HR+ HER2- Breast Cancer
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.6
2 insiders sold shares within a month
Since Jun 1, 2026 · was worth 10, fading over time
Worry score2
Score over time
- Stage
- Phase 1/2
- Patients
- 32 (planned)
- Started
- Apr 22, 2026
- Main results expected
- May 2029
- Fully finished
- May 2033
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Safety and tolerability of drugs by assessment of adverse events (AEs) / serious adverse events (SAEs)
Measured over: 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 1.6, since 2026-06-01, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07558733 · record last updated 2026-07-02 · checked 2026-11-09 15:36 UTC